Janssen Receives Positive CHMP Opinion on STELARA as Crohn’s Disease Treatment (JNJ)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Janssen-Cilag International NV (“Janssen”) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorisation in the European Union for the use of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist or have medical contraindications to such therapies. If approved, ustekinumab will offer people with Crohn’s disease a new treatment option to induce and maintain remission of their disease symptoms.1
“Crohn’s disease is a debilitating chronic condition that has a huge impact on patients’ quality of life. Patients experience unpredictable disease flares and many have lost response to currently available treatments, so it is vital that new therapeutic options are made available to help control their symptoms,” said Frederic Lavie, EMEA Therapeutic Area Leader Immunology, Cardiovascular and Metabolics, Janssen. “Ustekinumab has shown clinical benefit, is generally well tolerated, and has a convenient dosing regimen for people living with Crohn’s disease who are eligible for a biologic therapy.”
The CHMP adopted the opinion based on data from three pivotal Phase 3 trials which included approximately 1,400 patients with moderately to severely active Crohn’s disease:2,3,4
- UNITI-1 demonstrated significantly higher rates of clinical response at Week 6 for ustekinumab treatment groups compared with the placebo group (p=0.003) in patients who had failed on TNFα antagonist therapies.2 The major secondary endpoints of clinical remission at Week 8 and clinical response at Week 8 were each also significantly higher with IV ustekinumab induction versus IV placebo (p<0.001 for each).2 Clinical response was defined as a reduction from baseline in the Crohn’s Disease Activity Index (CDAI) score of ≥100 points or being in clinical remission. Clinical remission was defined as the CDAI <150.2 The CDAI is a symptom-based disease assessment tool that quantifies symptoms of Crohn’s disease and measures improvement with treatment.5
- UNITI-2 also demonstrated significantly greater clinical response at Week 6 with IV ustekinumab induction compared to IV placebo (p<0.001) in a population of patients who had previously failed conventional therapy, but who had not previously failed TNFα antagonist therapies. The secondary endpoints of clinical remission and response at Week 8 were also each both significantly higher in the ustekinumab groups compared to placebo (p<0.001 in each).3
- IM-UNITI studied maintenance in patients who achieved clinical response 8 weeks after a single IV infusion of ustekinumab in the UNITI-1 and UNITI-2 Phase 3 induction studies. IM-UNITI showed that a significantly greater proportion of patients in the subcutaneous ustekinumab maintenance groups was in clinical remission at Week 44 versus placebo (p=0.005 in every 8 week and p=0.040 in every 12 week groups; primary endpoint). Clinical response at Week 44 was also significantly greater with both regimens versus placebo at Week 44. Other major secondary endpoints of clinical remission at Week 44 among patients in remission after induction and corticosteroid-free remission were significantly greater for every 8 week ustekinumab maintenance versus placebo.4
Ustekinumab was generally well tolerated as an induction and maintenance therapy in all three studies, and the safety profile of ustekinumab in the Crohn’s disease clinical development program remained consistent with the established safety profile of ustekinumab based upon current labelled indications. In the induction studies (UNITI-1 and UNITI-2), through Week 8 (placebo-controlled period), adverse events (AEs), serious AEs (SAEs) and infections were reported in similar proportions across ustekinumab and placebo treatment groups.2,3 Through Week 44 (placebo-controlled period) in the maintenance study (IM-UNITI), AEs were reported in similar proportions across ustekinumab and placebo treatment groups, the majority of which were related to gastrointestinal disorders, such as abdominal pain and diarrhoea, and infections/infestations, of which, nasopharyngitis and upper respiratory infection were the most common. SAEs occurred in 10 percent, 12 percent and 15 percent of patients receiving ustekinumab 90 mg subcutaneously every 8 weeks, ustekinumab 90 mg subcutaneously every 12 weeks and placebo, respectively; 2 percent, 5 percent and 2 percent of patients reported serious infections in these respective groups. Through the 8-week induction and 44-week maintenance phases (representing 1 year total of therapy), no deaths or major adverse cardiovascular events were reported. Only two randomised patients reported malignancies (one case of basal cell carcinoma in the subcutaneous placebo group and another in the subcutaneous ustekinumab every 8 weeks group).4
Following this positive opinion, a final decision from the European Commission is expected later this year. Janssen is also currently seeking approval for ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease in the U.S.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the Street
- Bruker (BRKR) Acquires Hysitron
- Perrigo (PRGO) Reports FDA Approval of First-To-File AB Rated Generic Version of Topicort Spray, 0.25%
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!